Holen Sie sich die Stockscreener-App
48.71
2.14%
1.02
Handel nachbörslich:
48.52
-0.19
-0.39%
Schlusskurs vom Vortag:
$47.69
Offen:
$48.6
24-Stunden-Volumen:
796.51K
Relative Volume:
0.54
Marktkapitalisierung:
$3.46B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-218.28M
KGV:
-13.61
EPS:
-3.5803
Netto-Cashflow:
$-186.55M
1W Leistung:
+0.19%
1M Leistung:
+9.07%
6M Leistung:
+101.20%
1J Leistung:
+15.45%
1-Tages-Spanne:
$47.75
$49.28
1-Wochen-Bereich:
$45.50
$50.79
52-Wochen-Spanne:
$18.53
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Vergleichen Sie VERA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
48.71 | 3.39B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | BofA Securities | Buy |
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Vera Therapeutics hires offered stock in their pay packages - Stock Titan
What risks investors should watch in Vera Therapeutics Inc. stockCEO Change & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Sahm
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Is Vera Therapeutics Inc. stock gaining market share2025 Growth vs Value & AI Powered Market Entry Ideas - ulpravda.ru
Upcoming EventsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Detailed Stock Data - FinancialContent
Vera Therapeutics, Inc.'s (NASDAQ:VERA) Shift From Loss To Profit - 富途牛牛
Will Vera Therapeutics Inc. stock attract ESG investorsRisk Management & AI Powered Market Entry Ideas - ulpravda.ru
Is Vera Therapeutics Inc. stock a safe buy before earningsJuly 2025 Reactions & Community Driven Trade Alerts - ulpravda.ru
Biotech tackling serious immune diseases to speak at major SF forum - Stock Titan
Los Angeles Daily NewsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Stock Quote - FinancialContent
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ - openPR.com
Why Vera Therapeutics Stock Zoomed Higher Today - The Globe and Mail
FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review - Investing.com Nigeria
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review By Investing.com - Investing.com South Africa
Vera Therapeutics shares up 3% after co receives U.S. FDA priority review for kidney disease drug - MarketScreener
Vera Therapeutics' Atacicept Receives FDA Priority Review for Treatment of IgAN with PDUFA Date Set for July 7, 2026 - Quiver Quantitative
New weekly shot for serious kidney disease gets priority FDA review - Stock Titan
FDA Expedites Approval of Vera’s Home-Based Kidney Medication - Bitget
Wells Fargo sees short squeeze ahead: here are three stocks to play it - TradingView — Track All Markets
Vera Therapeutics Earnings Notes - Trefis
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Quarterly Earnings: Will Vera Therapeutics Inc stock attract ESG investors2025 Market Trends & Accurate Technical Buy Alerts - moha.gov.vn
Stock Traders Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA) - MarketBeat
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading - ts2.tech
Vera Therapeutics announces $200M public offering - MSN
Entry Recap: What risks investors should watch in Vera Therapeutics Inc stockJuly 2025 Momentum & Consistent Return Investment Signals - moha.gov.vn
Vera Therapeutics price target raised to $33 from $23 at Wedbush - MSN
50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB - MarketBeat
450,700 Shares in Vera Therapeutics, Inc. $VERA Acquired by Capricorn Fund Managers Ltd - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - ts2.tech
Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year HighShould You Buy? - MarketBeat
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects - Sahm
Vera Therapeutics Appoints James R. Meyers to Board - MSN
Vera’s New Capital Raise and Legal Transition Might Change The Case For Investing In Vera Therapeutics (VERA) - Sahm
How risky is Vera Therapeutics Inc. stock now2025 Market Overview & Smart Swing Trading Alerts - Улправда
Weekly Earnings: How Vera Therapeutics Inc. stock valuations compare to rivalsJuly 2025 EndofMonth & Momentum Based Trading Ideas - ulpravda.ru
Recap Report: Will Vera Therapeutics Inc. stock attract ESG investorsLong Setup & Long-Term Safe Investment Plans - moha.gov.vn
Vera Therapeutics, Inc. $VERA Shares Acquired by Squarepoint Ops LLC - MarketBeat
Goldman Sachs Maintains Vera Therapeutics (VERA) Buy Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 51.23 USD By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Vera Therapeutics Investors Drop Short-Swing Trading Lawsuit - Bloomberg Law News
Vera Therapeutics stock hits 52-week high at 51.23 USD - Investing.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Given New $96.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Is Vera Therapeutics Inc. stock oversold or undervalued2025 Market Trends & Fast Gain Swing Alerts - Улправда
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):